MediWound Ltd. (MDWD) carries a Roarable Rating of C- (Hold) with 60/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
As of 2026-11-01, MediWound Ltd. (NASDAQ: MDWD) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 60/100 at a spot price of $13.86 (+2.21% 1D, market cap $178.9M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, MDWD ranks #204 in composite RQD confidence.
Within the Health Care sector (Medicinal Chemicals and Botanical Products), MDWD carries a Roarable C- (60/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, NAGE (Niagen Bioscience Inc.) holds a C grade (63/100 RQD, P/E 11.4x, ROIC 16.8%, cap $197.8M) and GLAS (Glass House Brands Inc. Subordinate Voting Shares) posts a E grade (25/100 RQD, P/E N/A, ROIC -9.2%, cap $200.6M). Among the 5-stock peer group, NAGE leads on earnings multiple (11.4x) while NAGE leads on capital efficiency (16.8% ROIC).
For MediWound Ltd. (MDWD), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #204 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 26% of 52W Range • RSI-14 at 55.1 (BULLISH MOMENTUM)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment
Even with a 60/100 (C-) score, MDWD faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Company executives have done more routine share selling than personal cash buying lately.
Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($13.06) or 200D SMA ($15.24) invalidates the momentum regime and cuts Target Base ($13.98) toward Bear Floor ($10.90).
MediWound Ltd. (MDWD) surged +2.21% to $13.86, trading at 26% of its 52-week range ($11.8 – $19.7). Solid steady margins (steady margins), mixed timing at current multiples—hold if owned, no rush to chase.
MediWound to Report Third Quarter 2026 Financial Results Conference Call and Webcast Scheduled for Thursday, November 12th at 8:30 a.m. Eastern Time YAVNE, Israel, October 29, 2026 -- MediWound Ltd. (Nasdaq: MDWD), a glo
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on MDWD today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for MDWD. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, MediWound Ltd. (MDWD) ranks #204 by composite RQD confidence (60/100, grade C-) and #591 by equity capitalization ($178.9M). Within this direct 5-issuer industry benchmark cohort, NAGE leads on earnings valuation at 11.4x trailing P/E, while NAGE leads on capital efficiency and profitability with 16.8% ROIC and 64.3% gross margin. NAGE currently holds the highest overall quantitative score in the immediate peer group at 63/100 (C) compared with MDWD at 60/100 (C-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| MDWD
ACTIVE
MediWound Ltd. | C- | 60/100 | — | — | — | +2.21% | $178.9M | Benchmark Subject |
| NAGE Niagen Bioscience Inc. | C | 63/100 | 11.4x | 64.3% | 16.8% | -1.57% | $197.8M | /nage-vs-mdwd → |
| GLAS Glass House Brands Inc. Subordinate Voting Shares | E | 25/100 | — | 42.3% | -9.2% | +1.33% | $200.6M | /glas-vs-mdwd → |
| ACB Aurora Cannabis Inc. | D+ | 58/100 | — | — | — | 0.00% | $252.8M | /acb-vs-mdwd → |
| USNA USANA Health Sciences Inc. | C- | 61/100 | 24.6x | 78.3% | 7.9% | -1.91% | $265.0M | /usna-vs-mdwd → |
MediWound Ltd. (MDWD) operates in Medicinal Chemicals and Botanical Products (Health Care) with an equity capitalization of $178.9M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
As of 2026-11-01, MediWound Ltd. (NASDAQ: MDWD) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 60/100 at a spot price of $13.86 (+2.21% 1D, market cap $178.9M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, MDWD ranks #204 in composite RQD confidence.
Within the Health Care sector (Medicinal Chemicals and Botanical Products), MDWD carries a Roarable C- (60/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, NAGE (Niagen Bioscience Inc.) holds a C grade (63/100 RQD, P/E 11.4x, ROIC 16.8%, cap $197.8M) and GLAS (Glass House Brands Inc. Subordinate Voting Shares) posts a E grade (25/100 RQD, P/E N/A, ROIC -9.2%, cap $200.6M). Among the 5-stock peer group, NAGE leads on earnings multiple (11.4x) while NAGE leads on capital efficiency (16.8% ROIC).
For MediWound Ltd. (MDWD), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #204 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.
MDWD last traded at $13.86 (+2.21% on volume of 154,410 shares), positioning the stock +6.13% above its 50-day simple moving average ($13.06) and -9.06% below its 200-day simple moving average ($15.24). Across its 52-week range of $11.80 to $19.70, MDWD sits at the 26.1% percentile with a 14-day RSI of 55.1 (BULLISH MOMENTUM) and an implied next-earnings move of ±9.2% ($12.58 to $15.14).
Why MDWD Stock surged +2.21% Today — RQD Quant Desk Flash. Solid steady margins (steady margins), mixed timing at current multiples—hold if owned, no rush to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Paper Trading Arena account.